搜索筛选:
搜索耗时2.5250秒,为你在为你在102,285,761篇论文里面共找到 20 篇相符的论文内容
发布年度:
Study progression of recombinant human endostatin （Endostar） for the treatment of malignant serous e
[期刊论文] 作者：Ziyu Jiang,Shukui Qin,
来源：中德临床肿瘤学杂志：英文版 年份：2011
自从 recombinant 人 endostatin (rh-endostatin；Endostar ) 被列出了 5 年，临床医生们为肺癌症和另外的恶意的肿瘤的治疗把它与化疗相结合，并且证明了它的效果和安全。很多个...
,Study progression of anti-angiogenetic therapy and its combination with other agents for the treatm
[期刊论文] 作者：Xinlei Gong,Shukui Qin,
来源：肝胆外科与营养 年份：2018
Hepatocellular carcinoma (HCC) is a common malignancy worldwide and is especially prevalent in the Chinese population. Treatment of advanced HCC has posed a con...
[期刊论文] 作者：Ziyu Jiang,Shukui Qin,
来源：中德临床肿瘤学杂志（英文版） 年份：2004
Since recombinant human endostatin (rh-endostatin; Endostar) has been listed 5 years, clinicians have combined it with chemotherapy for the treatment of lung ca...
[会议论文] 作者：Xinlei Gong,Shukui Qin,
来源：第二十一届全国临床肿瘤学大会暨2018年CSCO学术年会 年份：2018
...
[期刊论文] 作者：Yizhou Luo,Shukui Qin,Xiaoqian,
来源：中德临床肿瘤学杂志（英文版） 年份：2004
Objective:To reveal the mechanism and effect of SU5416 in the treatment of mouse Lewis cancer in vivo.Methods:Lewis cell was transplanted into groin of C57/B6 m...
Continued application of Endostar combined with chemotherapy in advanced hemangioendothelioma of bon
[期刊论文] 作者：Ningrong Yang,Lin Wang,Xun Chen,Shukui Qin,
来源：中德临床肿瘤学杂志（英文版） 年份：2004
By one case of hemangioendothelioma of bone accompanying pulmonary metastasis was treated with rh-enostatin injection (Endostar) combined with chemotherapy. The...
The oral c-Met inhibitor MSC2156119J as monotherapy vs sorafenib in Asian patients with Met-positive
[会议论文] 作者：Shukui Qin,Ann-Lii Cheng,Ho Yeong Lim,Lianzhe Xu,Cindy Li,Friedhelm Bladt,
来源：第十七届全国临床肿瘤学大会暨2014年CSCO学术年会 年份：2014
...
The oral c-Met inhibitor MSC2156119J as monotherapy vs sorafenib in Asian patients with Met-positive
[会议论文] 作者：Shukui Qin,Ann-Lii Cheng,Ho Yeong Lim,Lianzhe Xu,Cindy Li,Friedhelm Bladt,
来源：第十七届全国临床肿瘤学大会暨2014年CSCO学术年会 年份：2014
Objective: Advanced hepatocellular carcinoma (HCC) is a leading cause of cancer death, particularly in Asia where ～80％ of HCC incidences occur.Although sorafenib is the recommended treatment, it is no...
[会议论文] 作者：Shukui Qin,Ho yeong Lim,Baek-yeol Ryoo,Cindy Li,Huiling Xiong,Christian Ihling,Ann-lii Cheng,
来源：第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 年份：2015
Objective: The overall prognosis of advanced hepatocellular cancer (HCC) remains poor, with c-Met abnormalities associated with a particularly poor prognosis.The highly selective c-Met inhibitor tepot...
First-line tepotinib (MSC2156119J), an oral c-Met inhibitor, versus sorafenib in Asian patients with
[会议论文] 作者：Shukui Qin,Ho yeong Lim,Baek-yeol Ryoo,Cindy Li,Huiling Xiong,Andreas Johne,Ann-lii Cheng,
来源：第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 年份：2015
Background: HCC, a poor-prognosis disease for which the only approved drug is sorafenib, has a high unmet need.Factors associated with tumor aggressiveness in advanced HCC include c-Met amplification/...
[会议论文] 作者：Shukui Qin,Feng Bi,Jie Jin,Ying Cheng,Jun Guo,Xiubao Ren,Yiran Huang,Connie Chen,Jamal Tarazi,Helen Bhattacharyya,
来源：第十六届全国临床肿瘤学大会暨2013年CSCO学术年会 年份：2013
...
[会议论文] 作者：Shukui Qin,Feng Bi,Jie Jin,Ying Cheng,Jun Guo,Xiubao Ren,Yiran Huang,Connie Chen,Jamal Tarazi,Helen Bhattacharyya,
来源：第十六届全国临床肿瘤学大会暨2013年CSCO学术年会 年份：2013
OBJECTIVE: In a registrational trial of second-line therapy in Asian patients with metastatic renal cell carcinoma (RCC), median progression-free survival (PFS), the primary endpoint, was 6.5 months w...
,XPA A23G polymorphism is associated with the elevated response to platinum-based chemotherapy in ad
[期刊论文] 作者：Jifeng Feng,Xinchen Sun,Ning Sun,Shukui Qin,Fan Li,Hongyan Cheng,Baoan Chen,YuanDong Cao,Jun Ma,Lu Cheng,
来源：生物化学与生物物理学报（英文版） 年份：2009
DNA repair capacity(DRC)is correlated with sensi tivity of cancer cells toward platinum-based chemotherapy.We hypothesize that genetic polymorphisms in DNA repa...
[会议论文] 作者：Yi-Long Wu,Shun Lu,Ying Cheng,Caicun Zhou,Mengzhao Wang,Shukui Qin,You Lu,Yang Zhang,Yunzhong Zhu,Helen,
来源：第十六届全国临床肿瘤学大会暨2013年CSCO学术年会 年份：2013
目的: It has been demonstrated that pemetrexed/cisplatin (A/C) has superior survival benefit and better safety profile over standard first line chemotherapy with gemcitabine/cisplatin (G/C) in patients...
[期刊论文] 作者：Jian Li,Yingjiang Ye,Jian Wang,Bo Zhang,Shukui Qin,Yingqiang Shi,Yulong He,Xiaobo Liang,Xiufeng Liu,Ye,
来源：中国癌症研究（英文版） 年份：2017
In order to further promote the standardization of diagnosis and treatment of gastrointestinal stromal tumor (GIST) in China,the members of Chinese Society of C...
A randomized,double-blind,multicenter,Phase2,three-arm,placebo-control study of apatinib as third li
[会议论文] 作者：Dongmei Ji,Xin Liu,weijian Guo,Jianping Xiong,Yuxian Bai,Guoping Sun,Yan Yang,Liwei Wang,Jin Li,Shukui Qin,
来源：第十五届全国临床肿瘤学大会暨2012年CSCO学术年会 年份：2012
...
A randomized,double-blind,multicenter,Phase2,three-arm,placebo-control study of apatinib as third li
[会议论文] 作者：Jin Li,Nong Xu,Ying Cheng,Zhehai Wang,Leizhen Zheng,Min Tao,xiaodong Zhu,Dongmei Ji,Xin Liu,Shukui Qin,
来源：第十五届全国临床肿瘤学大会暨2012年CSCO学术年会 年份：2012
...
Phase Ⅲ trial of afatinib vs erlotinib in patients (pts) with squamous cell carcinoma (SCC) of the l
[会议论文] 作者：Shun Lu,Wei Li,Caicun Zhou,Shukui Qin,Chengping Hu,Ki hyeong Lee,Young joo Min,Jin-hyoung Kang,Jong-seok,
来源：第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 年份：2015
Objective: Treatment options for pts with advanced SCC of the lung progressing after platinum-based chemotherapy are limited.Over expression of EGFR, other ErbB receptors and the dysregulation of thei...
RESORCE: An ongoing randomized, double-blind, placebo (Pbo)-controlled, phase Ⅲ trial of regorafenib
[会议论文] 作者：Shukui Qin,Jordi Bruix,Ligong Lu,Aimin Li,Jun Lv,Yimin Mao,Zhiqiang Meng,Tianqiang Song,Yongqiang Li,,
来源：第十七届全国临床肿瘤学大会暨2014年CSCO学术年会 年份：2014
Objective: No standard treatment options are available for HCC progressing despite SOR treatment.The oral multikinase inhibitor REG showed acceptable tolerability and antitumor activity in patients wi...
An open-label, randomized, multicenter study of S-1 vs Gemcitabine in patient with advanced pancreat
[会议论文] 作者：Jianming Xu,Yan Sun,Liwei Wang,Ruihua Xu,Yi Ba,Lin Shen,Shukui Qin,Nong Xu,Li Bai,Jin Li,Chunmei Bai,,
来源：第十八届全国临床肿瘤学大会暨2015年CSCO学术年会 年份：2015
Objective: Gemcitabine (GEM) is a standard treatment in patients with advanced pancreatic cancer (PC).S-1 has shown a good efficacy and well safety in Japanese patients from previous studies and has b...
相关搜索：
